Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inamed Plans FDA Dealings: Panel First, Data Request For Style 410 Second

This article was originally published in The Gray Sheet

Executive Summary

Inamed will delay a response to FDA's request for more information regarding the next-generation Style 410 Cohesive silicone gel breast implants until after next week's advisory panel on the first-generation version

You may also be interested in...



Inamed’s Amended Silicone Breast Implant PMA Sheds Style 153 Model

Inamed expects its modified silicone breast implant premarket approval application to receive FDA approval by the end of the summer

Inamed’s Amended Silicone Breast Implant PMA Sheds Style 153 Model

Inamed expects its modified silicone breast implant premarket approval application to receive FDA approval by the end of the summer

Inamed To File Next-Gen Breast Implant PMA, Lap-Band NCD Request Soon

Inamed will file a PMA for its Cohesive Silicone Gel Matrix breast implant on Dec. 6, the firm says

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel